Development of NanoManganese for the optimization of radiotherapy in cancer treatment » PACA’s economic and political newsletter

Medesis Pharma, a pharmaceutical biotechnology company developing drug candidates with its proprietary oral active delivery technology.

Aonys® today announces positive results in the development program of its drug candidate NanoManganese, as a radioprotective agent in cancers treated by radiotherapy.

Optimization of the efficacy and safety of radiotherapy in the treatment of cancers

The principle of radiotherapy in cancer is to cause cancer cell death while limiting damage to normal cells. Radiation therapy used to treat cancer is based on the assumption that due to their high proliferation rate and low DNA repair activity, cancer cells are more sensitive to radiation than healthy tissue. Radiation therapy-induced irradiation causes direct DNA damage resulting in cell death and also causes the generation of free radicals by radiolysis of water resulting in DNA damage in cancer cells and normal cells.

Thus, radiotherapy is associated with toxicity which can be serious and cause permanent damage and with early adverse effects, during or within two weeks after radiotherapy, associated with the generation of free radicals.

NanoManganese combines Aonys® technology with the manganese ion, delivering manganese in the cationic state intracellularly. Manganese Superoxydismutase (MnSOD) is essential in the mechanisms of elimination of intracellular free radicals and regulation of oxidative stress. NanoManganese by its MnSOD-like activity helps eliminate free radicals and limits oxidative stress.

In studies carried out on irradiated mouse models in collaboration with the Institute for Biomedical Research of the Armed Forces (IRBA), NanoManganese considerably increased the survival of mice, demonstrating its anti-radical activity and supporting its potential to protect healthy tissues from radiation toxicity. On the strength of these initial results, Medesis Pharma initiated a study at the end of 2021 on a mouse model (mouse) of glioblastoma (cancer of brain tissue) treated with radiotherapy. The objective was to prove that NanoManganese does not reduce the effect of radiotherapy on cancer cells.

Following this study, it was demonstrated that treatment with NanoManganese maintains the effectiveness of radiotherapy on tumor cells. The results also show a trend towards a potential of NanoManganese to sensitize tumor cells to radiation, mechanistically confirmed in the literature. This could mean that NanoManganese could not only protect healthy tissue from radiotherapy toxicity, but also potentiate the effectiveness of radiotherapy on tumor cells. The continuation of this preclinical work on the effectiveness of NanoManganese associated with Aonys technology in the treatment of cancers by radiotherapy is included in the financing plan presented on April 13, 2022 for the current year. Their validation will be followed by a clinical Phase II which will be prepared at the end of 2022 for implementation in H1 2023. The financing plan will be determined in the coming months, specifying that a call for the market will be preferred, subject to market conditions.

The financing methods will be determined according to the progress of the current programs and the best estimated opportunities. Up to 60% of patients diagnosed with cancer will receive radiation therapy as part of their treatment. (https://www.fondation-arc.org/treatments-soins-cancer/radiotherapie/quest-ce-que-la-radiotherapie).

Radiation therapy is effective and very cost-effective, with this treatment modality accounting for only about 5% of the total cost of cancer care. Any improvement in the efficacy and safety of radiotherapy will therefore benefit a very large number of patients.

About Medesis Pharma

To advance in the treatment of serious diseases for which there is no effective treatment, Medesis Pharma designs drug candidates based on its proprietary Aonys® technology for administering active ingredients in the form of nano-droplets by oral route, which makes the delivery of active ingredients in all cells, with passage of the Blood-Brain Barrier

This innovative approach is applied to future drugs to treat major diseases lacking effective treatments: Alzheimer’s disease, Huntington’s disease, genetic diseases, resistant cancers and severe respiratory inflammations such as those linked to COVID-19 . Medesis Pharma also develops treatments dedicated to populations irradiated after a civil or military nuclear accident. A French biopharmaceutical company based near Montpellier, Medesis Pharma is the source of 15 scientific publications, holds 11 patents, the fruit of 17 years of research and is now more particularly dedicated to 3 projects in the field of neurodegenerative diseases and the treatment of Covid-19. Recognized worldwide, Medesis Pharma is also working on new applications of its technology in partnership with public research laboratories (CNRS, CEA, IRBA), major university hospital centers in France, Canada and the United States as well as players private, like Transgene. Medesis Pharma shares are listed on Euronext Growth Paris: FR001844464 – ALMDP

Leave a Comment